Commentary

Video

The Impact of the Ponatinib FDA Approval in Newly Diagnosed Ph+ ALL

Author(s):

Ibrahim Aldoss, MD, City of Hope Comprehensive Cancer CenterElias Jabbour, MD, MD Anderson Cancer Center

Ibrahim T. Aldoss, MD; and Elias Jabbour, MD, discuss the impact of the FDA approval of ponatinib for the treatment of newly diagnosed patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.

Related Videos
Joseph Maakaron, MD, assistant professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Marie Hu, MD, assistant professor, medicine, Division of Hematology, Oncology and Transplantation, the University of Minnesota Medical School
Harry P. Erba, MD, PhD
Radhika Bansal, MBBS
Allison Winter, MD
Andrew Ip, MD
Eric Winer, MD
Monzr M. Al Malki, MD
Ibrahim T. Aldoss, MD; and Elias Jabbour, MD
Antonio Martin Jimenez Jimenez, MD
Related Content
FDA
June 27th 2024

FDA Modifies REMS for Autologous CAR T-Cell Therapies in Hematologic Malignancies

Stephen Liu, MD; Sara A. Hurvitz, MD, FACP; S. Vincent Rajkumar, MD; Sumanta Kumar Pal, MD, FASCO; Shubham Pant, MD, MBBS
May 23rd 2024

Oncology Experts Preview Top Abstracts From the 2024 ASCO Annual Meeting

Jeremy Abramson, MD, of Massachusetts General Hospital
June 27th 2024

Liso-cel Shows Improved EFS, PFS, and Durable Responses in Second-line LBCL at 3 Years

Elias Jabbour, MD, professor, medicine, Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
April 8th 2024

FDA Approval Insights: Ponatinib in Ph+ ALL

FDA
June 24th 2024

FDA Approves Crovalimab for Paroxysmal Nocturnal Hemoglobinuria

Barbara Jane O’Brien, MD, of The University of Texas MD Anderson Cancer Center
June 21st 2024

Tucatinib-Based Regimen Improves Target Deficits, QOL in HER2+ Breast Cancer With Leptomeningeal Metastasis